Table 1.
Baseline characteristics of HCM patients.
Values are given as total number of patients (n) or as mean ± SD.
Table 2.
Influence of disease related factors and medication on the orthostatic test result in 69 HCM patients older than or equal to 40 years.
Table 3.
Influence of disease related factors and medication on the QTc interval in 100 HCM patients.
Fig 1.
Impact of orthostatic test on the occurrence of adverse events in HCM patients for all patients (A) and for the subgroup of patients > 40 yrs (B).
Sensitivity, specificity, PPV (positive predictive value), NPV (negative predictive value) and OR (odds ratio; adjusted for age and sex) with 95%-CI (confidence intervals) are given in the table below. AE = adverse events (syncope, presyncope, VT).
Fig 2.
Impact of QTc prolongation on the occurrence of adverse events in HCM patients.
Sensitivity, specificity, PPV (positive predictive value), NPV (negative predictive value) and OR (odds ratio; adjusted for age and sex) with 95%-CI (confidence intervals) are given in the table below. AE = adverse events (syncope, presyncope, VT).
Fig 3.
Relationship between orthostatic test result and QTc prolongation.
The percentages of patients with a positive and negative orthostatic test result are given for the group with and without QTc prolongation.